Cargando…

Stigma trajectories among people living with HIV (PLHIV) embarking on a life time journey with antiretroviral drugs in Jinja, Uganda

BACKGROUND: Stigma is a barrier to HIV prevention and treatment. There is a limited understanding of the types of stigma facing people living with HIV (PLHIV) on antiretroviral therapy (ART). We describe the stigma trajectories of PLHIV over a 5-year period from the time they started ART. METHODS: L...

Descripción completa

Detalles Bibliográficos
Autores principales: Mbonye, Martin, Nakamanya, Sarah, Birungi, Josephine, King, Rachel, Seeley, Janet, Jaffar, Shabbar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3844351/
https://www.ncbi.nlm.nih.gov/pubmed/24010761
http://dx.doi.org/10.1186/1471-2458-13-804
_version_ 1782293163667357696
author Mbonye, Martin
Nakamanya, Sarah
Birungi, Josephine
King, Rachel
Seeley, Janet
Jaffar, Shabbar
author_facet Mbonye, Martin
Nakamanya, Sarah
Birungi, Josephine
King, Rachel
Seeley, Janet
Jaffar, Shabbar
author_sort Mbonye, Martin
collection PubMed
description BACKGROUND: Stigma is a barrier to HIV prevention and treatment. There is a limited understanding of the types of stigma facing people living with HIV (PLHIV) on antiretroviral therapy (ART). We describe the stigma trajectories of PLHIV over a 5-year period from the time they started ART. METHODS: Longitudinal qualitative in-depth interviews were conducted with 41 members of The AIDS Support Organisation (TASO) from 2005 to 2008 in Jinja, Uganda, who were part of a pragmatic cluster-randomised trial comparing two different modes of ART delivery (facility and home). Participants were stratified by gender, ART delivery arm and HIV stage (early or advanced) and interviewed at enrolment on to ART and then after 3, 6, 18 and 30 months. Interviews focused on stigma and ART experiences. In 2011, follow-up interviews were conducted with 24 of the participants who could be traced. Transcribed texts were translated, coded and analyzed thematically. RESULTS: Stigma was reported to be very high prior to starting ART, explained by visible signs of long-term illnesses and experiences of discrimination and abuse. Early coping strategies included: withdrawal from public life, leaving work due to ill health and moving in with relatives. Starting ART led to a steady decline in stigma and allowed the participants to take control of their illness and manage their social lives. Better health led to resumption of work and having sex but led to reduced disclosure to employers, colleagues and new sexual partners. Some participants mentioned sero-sorting in order to avoid questions around HIV sero-status. A rise in stigma levels during the 18 and 30 month interviews may be correlated with decreased disclosure. By 2011, ART-related stigma was even more pronounced particularly among those who had started new sexual relationships, gained employment and those who had bodily signs from ART side-effects. CONCLUSION: This study has shown that while ART comes with health benefits which help individuals to get rid of previously stigmatising visible signs, an increase in stigma may be noticed after about five years on ART, leading to reduced disclosure. ART adherence counselling should reflect changing causes and manifestations of stigma over time.
format Online
Article
Text
id pubmed-3844351
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-38443512013-12-02 Stigma trajectories among people living with HIV (PLHIV) embarking on a life time journey with antiretroviral drugs in Jinja, Uganda Mbonye, Martin Nakamanya, Sarah Birungi, Josephine King, Rachel Seeley, Janet Jaffar, Shabbar BMC Public Health Research Article BACKGROUND: Stigma is a barrier to HIV prevention and treatment. There is a limited understanding of the types of stigma facing people living with HIV (PLHIV) on antiretroviral therapy (ART). We describe the stigma trajectories of PLHIV over a 5-year period from the time they started ART. METHODS: Longitudinal qualitative in-depth interviews were conducted with 41 members of The AIDS Support Organisation (TASO) from 2005 to 2008 in Jinja, Uganda, who were part of a pragmatic cluster-randomised trial comparing two different modes of ART delivery (facility and home). Participants were stratified by gender, ART delivery arm and HIV stage (early or advanced) and interviewed at enrolment on to ART and then after 3, 6, 18 and 30 months. Interviews focused on stigma and ART experiences. In 2011, follow-up interviews were conducted with 24 of the participants who could be traced. Transcribed texts were translated, coded and analyzed thematically. RESULTS: Stigma was reported to be very high prior to starting ART, explained by visible signs of long-term illnesses and experiences of discrimination and abuse. Early coping strategies included: withdrawal from public life, leaving work due to ill health and moving in with relatives. Starting ART led to a steady decline in stigma and allowed the participants to take control of their illness and manage their social lives. Better health led to resumption of work and having sex but led to reduced disclosure to employers, colleagues and new sexual partners. Some participants mentioned sero-sorting in order to avoid questions around HIV sero-status. A rise in stigma levels during the 18 and 30 month interviews may be correlated with decreased disclosure. By 2011, ART-related stigma was even more pronounced particularly among those who had started new sexual relationships, gained employment and those who had bodily signs from ART side-effects. CONCLUSION: This study has shown that while ART comes with health benefits which help individuals to get rid of previously stigmatising visible signs, an increase in stigma may be noticed after about five years on ART, leading to reduced disclosure. ART adherence counselling should reflect changing causes and manifestations of stigma over time. BioMed Central 2013-09-05 /pmc/articles/PMC3844351/ /pubmed/24010761 http://dx.doi.org/10.1186/1471-2458-13-804 Text en Copyright © 2013 Mbonye et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Mbonye, Martin
Nakamanya, Sarah
Birungi, Josephine
King, Rachel
Seeley, Janet
Jaffar, Shabbar
Stigma trajectories among people living with HIV (PLHIV) embarking on a life time journey with antiretroviral drugs in Jinja, Uganda
title Stigma trajectories among people living with HIV (PLHIV) embarking on a life time journey with antiretroviral drugs in Jinja, Uganda
title_full Stigma trajectories among people living with HIV (PLHIV) embarking on a life time journey with antiretroviral drugs in Jinja, Uganda
title_fullStr Stigma trajectories among people living with HIV (PLHIV) embarking on a life time journey with antiretroviral drugs in Jinja, Uganda
title_full_unstemmed Stigma trajectories among people living with HIV (PLHIV) embarking on a life time journey with antiretroviral drugs in Jinja, Uganda
title_short Stigma trajectories among people living with HIV (PLHIV) embarking on a life time journey with antiretroviral drugs in Jinja, Uganda
title_sort stigma trajectories among people living with hiv (plhiv) embarking on a life time journey with antiretroviral drugs in jinja, uganda
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3844351/
https://www.ncbi.nlm.nih.gov/pubmed/24010761
http://dx.doi.org/10.1186/1471-2458-13-804
work_keys_str_mv AT mbonyemartin stigmatrajectoriesamongpeoplelivingwithhivplhivembarkingonalifetimejourneywithantiretroviraldrugsinjinjauganda
AT nakamanyasarah stigmatrajectoriesamongpeoplelivingwithhivplhivembarkingonalifetimejourneywithantiretroviraldrugsinjinjauganda
AT birungijosephine stigmatrajectoriesamongpeoplelivingwithhivplhivembarkingonalifetimejourneywithantiretroviraldrugsinjinjauganda
AT kingrachel stigmatrajectoriesamongpeoplelivingwithhivplhivembarkingonalifetimejourneywithantiretroviraldrugsinjinjauganda
AT seeleyjanet stigmatrajectoriesamongpeoplelivingwithhivplhivembarkingonalifetimejourneywithantiretroviraldrugsinjinjauganda
AT jaffarshabbar stigmatrajectoriesamongpeoplelivingwithhivplhivembarkingonalifetimejourneywithantiretroviraldrugsinjinjauganda